摘要
Aim: A bridging study of INTRIGUE study to assess the efficacy and safety of ripretinib versus sunitinib as second -line treatment in Chinese GIST patients. Methods: This was a phase 2, multicenter, randomized, open-label study in China. GIST patients previously treated with imatinib were randomized (1:1) to receive ripretinib 150 mg once daily (QD) by continuous dosing in 42-day cycles or sunitinib 50 mg QD in 42-day cycles (four weeks on/two weeks off). Primary endpoint was progression-free survival (PFS) by independent radiological review (IRR). Results: Between 6 December 2020 and 15 September 2021, 108 patients were randomized to receive ripretinib (n = 54) or sunitinib (n = 54) (all-patient [AP] intention-to-treat [ITT] population). Seventy patients had pri-mary KIT exon 11 mutations (ripretinib, n = 35; sunitinib, n = 35; Ex11 ITT population). By data cut-off (20 July 2022), in AP ITT population, PFS by IRR was comparable between ripretinib and sunitinib arms (HR 0.99, 95 % CI 0.57, 1.69; nominal p = 0.92; median PFS [mPFS] 10.3 vs 8.3 months). In Ex11 ITT population, PFS by IRR was longer for ripretinib than sunitinib (HR 0.46, 95 % CI 0.23, 0.92; nominal p = 0.03; mPFS not reached in ripretinib arm and 4 & sdot;9 months in sunitinib arm). Fewer patients experienced grade 3/4 treatment-related treatment-emergent adverse events with ripretinib (17%) versus sunitinib (56%). Conclusions: Ripretinib demonstrated similar efficacy and a favorable safety profile versus sunitinib as second -line treatment in Chinese GIST patients. Furthermore, ripretinib provided greater clinically meaningful benefit versus sunitinib in patients with KIT exon 11 mutation.
学科与关键词
- Efficacy and safety of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2 multicenter, randomized, openlabel study in China.Li, Jian; Zhang, Jun; Zhang, Yanqiao; Qiu, Haibo; Zhou, Yanbing; Zhou, Yongjian; Zhang, Xinhua; Zhou, Ye; Zhu, Yuping; Li, Yong; Wang, Ming; Shen, Kuntang; Tao, Kaixiong; Wu, Xin; Wang, Haijiang; Zhang, Bo; Ling, Jiayu; Ye, Yingjiang; Dong, Juan; Shen, LinGenitourinary Cancers Symposium, San Francisco, CA, 2023-01-19 To 2023-01-21.被引 1
- Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter StudyLi, Jian; Zhang, Xinhua; Deng, Yanhong; Wu, Xin; Zheng, Zhichao; Zhou, Yongjian; Cai, Shirong; Zhang, Yanqiao; Zhang, Jun; Tao, Kaixiong; Cui, Yuehong; Cao, Hui; Shen, Kuntang; Yu, Jiren; Zhou, Ye; Ren, Wenxiao; Qu, Chenglin; Zhao, Wanqi; Hu, Jin; Wang, Wei; Yang, Jason; Shen, Lin*ONCOLOGIST, 2023, 28(2): 187-+.被引 3
- Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro StudyZhou, Yongjian; Zeng, Chunling; Sun, Xiaofeng; Zhang, Jun; Qu, Hongyan; Zhang, Xinhua; Zhou, Ye; Liu, Zimin; Wu, Xiaojun; Wu, Xin; Jiao, Xuelong; Shen, Lin; Zhou, Yanbing*; Wang, Yuexiang*; Li, Jian*ONCOLOGIST, 2023.
